Cancer supportive care is
associated with care given to the patients suffering from various types of
cancer. Supportive care is intended for relieving suffering of the patients and
improving their quality of life.
Statistics:
The global Cancer
Supportive Care Products Market was estimated to account for US$ 27,244. Mn
in terms of value by the end of 2019.
Global Cancer Supportive Care
Products Market: Drivers
Availability of effective cancer
supportive care products is expected to propel growth of the global cancer
supportive care products market over the forecast period. For instance,
according to a study presented at the recent Digital International Liver
Congress (ILC 2020), Stivarga (regorafenib) and Opdivo (nivolumab), when
administered as second-line treatments, equally improve survival for people
with hepatocellular carcinoma (HCC), the most common type of liver cancer.
Global Cancer Supportive Care
Products Market: Opportunities
R&D in drug delivery in
cancer pain care is expected to offer lucrative growth opportunities for
players in the global cancer supportive care products market. For instance, in
August 2020, a study by Center for Pain and Supportive Care in Phoenix,
Arizona, U.S., supported the use of intrathecal drug delivery in cancer pain
care.
Global Cancer Supportive Care
Products Market: Restraints
Rising cost of R&D is
expected to hinder growth of the global cancer supportive care products market.
A new study ‘Estimated Research and Development Investment Needed to Bring a
New Medicine to Market, 2009-2018’, published in March 2020 estimated that the
median cost of getting a new drug into the market was US$ 985 million.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2013
Key Takeaways:
The global cancer supportive care
products market was valued at US$ 27,244.1 Mn in 2019 and is forecast to reach
a value of US$ 40,884.0 Mn by 2027 at a CAGR of 4.6% between 2020 and
2027.Increseing prevalence of cancer in developing and developed economies is
expected to drive the market growth during the forecast period.
Erythropoietin Stimulating Agents
segment held dominant position in the global cancer supportive care products
market in 2019, accounting for 24.7% share in terms of value, increasing
research and development along with product approvals is expected to assist the
segment growth during the forecast period.
Market Trends
Emergence of COVID‐19 has impacted
cancer supportive care. For instance, the French Society of Pediatric Oncology,
in September 2020, reported that, in a survey, out of the 12 centers that
managed COVID‐19 patients, eight centers declared having postponed a specific
oncologic treatment because of suspected or confirmed infection. Eight centers
(28.6%) declared facing health care providers’ absenteeism because of
infection.
Launch of cancer care quality
improvement model is expected to propel growth of the global cancer supportive
care products market over the forecast period. For instance, in August 2020, a
quality improvement tool called “Improving Care Coordination: A Model for Lung
Cancer” was released by the Association of Community Cancer Centers (ACCC).The
model framework can be used by cancer care providers to improve care
coordination for patients with lung cancer who are covered by Medicaid.
Regulations
Regulations (EU) - Cancer
Supportive Care
Approval Process
Cancer drugs are licensed in the
EU by the EMA and their various regulatory aspects can be found under
directives 2001/83/EC, CPMP/EWP/83561/2005, CPMP/EWP/2330/99 and others
EMA also recommends understanding
the drug-drug interactions assessment, mass-balance studies related to
pharmacokinetics of cancer-supportive drugs
Assessment of drug-drug
interaction are also strongly recommended under directive CPMP/EWP/560/95/Rev.1
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/cancer-supportive-care-drugs-market-2013
Special instructions from EMA and
EFPIA for development of products to be used for cancer supportive care
Clinical efficacy measurement of
the drug should strongly be inclined towards adequacy of management of nausea
and vomiting – even if delayed
Acronyms and tables detailing
nausea and vomiting symptoms, along with their pathophysiology should be well
documented
There needs to be more emphasis
on understanding the carryover effect between controlling chemotherapy induced
emesis symptoms. As such, the EFPIA has recommended randomization of at least
one drug approval trial
Further, it is inappropriate to
mention only one drug as a standard therapy e.g. NK1 receptor antagonist as a
standard antiemetic therapy. It is better from the ethical standpoint to
mention comparable drug data form the research perspective
Global Cancer Supportive Care
Products Market: Competitive Landscape
Major players operating in the
global cancer supportive care products market include, Amgen Inc., Johnson
& Johnson Private Ltd., Merck, Novartis AG, Baxter International,
Hoffmann-La Roche Ltd., Fagron, Teva Pharmaceutical Industries Ltd., G1 Therapeutics
Inc., APR Applied Pharma Research s.a., Acacia Pharma, EMD Serono, and Kyowa
Hakko Kirin Co., Ltd.
Global Cancer Supportive Care Products
Market: Key Developments
Major players in the market are
focused on approval and launch of new products to expand their product
portfolio. For instance, For instance, in August 2020, G1 Therapeutics Inc.
received the U.S. FDA’s priority review designation to a new drug application
(NDA) for trilaciclib for the treatment of patients with small cell lung cancer
(SCLC) who are being treated with chemotherapy.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2013
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment